Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group


1Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA; 2Section of Biostatistics, Mayo Clinic, Scottsdale, AZ, USA; 3Oregon Health Sciences University, Portland, OR, USA; 4Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands; 5Department of Hematology, Erasmus MC, Rotterdam, the Netherlands; 6MPN Forum, Ashville, NC, USA; 7Department of Hematology, MUMC, Maastricht, the Netherlands; 8Fundaleu, Buenos Aires, Argentina; 9Department of Haematology, University Hospital La Paz, Madrid, Spain; 10Department of Molecular Hematology, University Hospital Freiburg, Germany; 11Johannes Wesling Klinikum, Minden, Germany; 12Department of Internal Medicine III, University Hospital of Ulm, Germany; 13Hematology Department, University Hospital, Basel, Switzerland; 14Medizinische Klinik, Universitätsmedizin, Mannheim, Germany; 15Centre Hospitalier Universitaire, Angers, France; 16Institut Bergonie, Bordeaux, France; 17Centre Hospitalier Universitaire, Brest, France; 18Hospitalier Universitaire, Nancy, France; 19Centre Hospitalier Universitaire, Poitiers, France; 20Centre Hospitalier Universitaire, Grenoble, France; 21Department of Haematology, Guy’s and St. Thomas NHS Foundation Trust, London, UK; 22Unidadde Hematología, Hospital Británico, Montevideo, Uruguay; 23University of Puerto Rico School of Medicine, San Juan, Puerto Rico; 24Hematology Department, Hospital del Mar, Barcelona, Spain; 25Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Spain; 26Internal Medicine, NU Hospital Organization, Uddevalla, Sweden; 27Research Foundation (FROM), Hospital Papa Giovanni XXIII, Bergamo, Italy; 28Laboratory of Clinical Epidemiology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy; 29Center for Research and Innovation of Myeloproliferative Neoplasms, University of Florence, Italy; 30Ematologia, Dipartimento di Medicina Clinica e Sperimentale, University of Insulbria, Varese, Italy; 31Biol. Sci., Ospedali Riuniti di Bergamo, Italy; 32Department of Internal Medicine, Stockholm South Hospital, Sweden; 33Department of Hematology, University Hospital, Upsala, Sweden; 34MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; 35Clinical Investigation Center, Hospital Saint-Louis, Paris, France; 36Department of Pathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; 37Imperial College, London, UK and 38Department of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA

©2017 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2016.149559

Received: May 19, 2016.
Accepted: August 12, 2016.
Pre-published: August 18, 2016.
Correspondence: mesa.ruben@mayo.edu or geyer.holly@mayo.edu
Appendix 1: MPN-SAF PRO Development and Validation

The MPN-SAF included existing questions from the Myelofibrosis Symptom Assessment Form (MF-SAF; fatigue, early satiety, abdominal pain, abdominal discomfort, inactivity, cough, night sweats, pruritus, bone pain, fever, weight loss and quality of life) and was expanded to include ‘problems with concentration’, ‘difficulty sleeping’, ‘numbness/tingling’, ‘depression or sad mood’ and ‘problems with sexual desire or function’. All questions were scored on a scale from 0 (as good as it can be/absent) to 10 (as bad as it can be/worst-imaginable). The survey was drafted in English format and translated into other languages via an established Patient Reported Outcome translation method. Translation for each language involved three independent survey translations created by translators fluid in both English and the respective language requiring translation. A fourth translator then compares the three translator manuscripts to develop a consensus translation.

Upon completion of the survey, patients were recruited from academic, government-funded and private practice international medical centers. Patients were requested to self-complete the MPN-SAF during an office visit. Patients were also provided the opportunities to include additional symptoms omitted from the survey via open-ended questions.
Physicians who were blinded to patient responses were required to rank patient symptoms on the same 0-10 scale as well as document patient disease status including laboratory data, treatment history and prognostic scores. Anova F tests or 2-sample t tests were used to assess continuous variables whereas $\chi^2$ tests were used to compare categorical variables. The relationships between variables was assessed using Pearson correlations. Patient scores between language groups were adjusted by disease type using general linear models and intraclass correlation coefficient (ICC) was analyzed on the basis of a 2-way ANOVA model.